Literature DB >> 27417181

Characteristic Analysis of Intestinal Transport in Enterocyte-Like Cells Differentiated from Human Induced Pluripotent Stem Cells.

Nao Kodama1, Takahiro Iwao2, Takahiro Katano1, Kinya Ohta1, Hiroaki Yuasa1, Tamihide Matsunaga1.   

Abstract

We previously demonstrated that differentiated enterocytes from human induced pluripotent stem (iPS) cells exhibited drug-metabolizing activities and cytochrome P450 CYP3A4 inducibility. The aim of this study was to apply human iPS cell-derived enterocytes in pharmacokinetic studies by investigating the characteristics of drug transport into enterocyte-like cells. Human iPS cells cultured on feeder cells were differentiated into endodermal cells using activin A. These endodermal-like cells were then differentiated into intestinal stem cells by fibroblast growth factor 2. Finally, epidermal growth factor and small-molecule compounds induced the maturation of the intestinal stem cell-like cells. After differentiation, we performed transepithelial electrical resistance (TEER) measurements, immunofluorescence staining, and transport studies. TEER values increased in a time-dependent manner and reached approximately 100 Ω × cm(2) Efflux transport of Hoechst 33342, a substrate of breast cancer resistance protein (BCRP), was observed and inhibited by the BCRP inhibitor Ko143. The uptake of peptide transporter 1 substrate glycylsarcosine was also confirmed and suppressed when the temperature was lowered to 4°C. Using immunofluorescence staining, villin and Na(+)-K(+) ATPase were expressed. These results suggest that human iPS cell-derived enterocytes had loose tight junctions, polarity, as well as uptake and efflux transport functions. In addition, the rank order of apparent membrane permeability coefficient (Papp) values of these test compounds across the enterocyte-like cell membrane corresponded to the fraction absorbance (Fa) values. Therefore, differentiated enterocytes from human iPS cells may provide a useful comprehensive evaluation model of drug transport and metabolism in the small intestine.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27417181     DOI: 10.1124/dmd.116.069336

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

1.  Using human iPS cell-derived enterocytes as novel in vitro model for the evaluation of human intestinal mucosal damage.

Authors:  Satoshi Kondo; Shota Mizuno; Tadahiro Hashita; Takahiro Iwao; Tamihide Matsunaga
Journal:  Inflamm Res       Date:  2018-10-13       Impact factor: 4.575

2.  Establishment of a novel culture method for maintaining intestinal stem cells derived from human induced pluripotent stem cells.

Authors:  Satoshi Kondo; Shota Mizuno; Tadahiro Hashita; Takahiro Iwao; Tamihide Matsunaga
Journal:  Biol Open       Date:  2020-01-09       Impact factor: 2.422

3.  Generation of Human-Induced Pluripotent Stem Cell-Derived Functional Enterocyte-Like Cells for Pharmacokinetic Studies.

Authors:  Shinpei Yoshida; Takayuki Honjo; Keita Iino; Ryunosuke Ishibe; Sylvia Leo; Tomoka Shimada; Teruhiko Watanabe; Masaya Ishikawa; Kazuya Maeda; Hiroyuki Kusuhara; Nobuaki Shiraki; Shoen Kume
Journal:  Stem Cell Reports       Date:  2021-01-28       Impact factor: 7.765

4.  Toward Xeno-Free Differentiation of Human Induced Pluripotent Stem Cell-Derived Small Intestinal Epithelial Cells.

Authors:  Jaakko Saari; Fatima Siddique; Sanna Korpela; Elina Mäntylä; Teemu O Ihalainen; Katri Kaukinen; Katriina Aalto-Setälä; Katri Lindfors; Kati Juuti-Uusitalo
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

5.  A Versatile Human Intestinal Organoid-Derived Epithelial Monolayer Model for the Study of Enteric Pathogens.

Authors:  Stefania Senger; Christina S Faherty; Kourtney P Nickerson; Alejandro Llanos-Chea; Laura Ingano; Gloria Serena; Alba Miranda-Ribera; Meryl Perlman; Rosiane Lima; Marcelo B Sztein; Alessio Fasano
Journal:  Microbiol Spectr       Date:  2021-06-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.